CURRENT ADVANCES AND ROLE OF INTERVENTIONAL RADIOLOGY IN MANAGEMENT OF HEPATOCELLULAR CARCINOMA

Maria rauf

Abstract


OBJECTIVE:To understand the treatment options and their effectiveness in the management of hepatocellular carcinoma (HCC) offered by interventional radiologists. The role of interventional radiology (IR) in management of HCC have come to forefront over the last two decades. IR also plays a role in preoperative management of HCC patients as these treatment options may serve as bridge to liver transplant. The recently updated Barcelona Clinic Liver Cancer (BCLC) staging system for HCC provides a guideline for choosing the optimum treatment modality for individual patients, with IR playing a central role. Methods:After approval from IRB and EC of Shifa international hospital we retrospectively reviewed the patients managed for HCC at out IR unit from January 2017 to June 2024 and we categorized the management options for HCC broadly as percutaneous therapies and trans arterial therapies: The treatment options for HCC can be categorized broadly as;1- Percutaneous therapies: these include         a. Thermal therapies including Radiofrequency Ablation and Microwave ablation         b. Percutaneous Ethanol injection 2- Trans-arterial therapies: these include         a. Trans-arterial bland embolization          b. Trans-arterial chemoembolization          c. Trans-arterial radioembolization          d. Intra-arterial ethanol injection Conclusion: Interventional therapy plays a vital role in management of HCC at all the stages. Interventional radiology treatments are typically well-received and provide therapeutic choices that minimize both the associated health complications and expenses, serving the purposes of palliation and potential cure.Key words:Hepatocellular carcinoma, interventional radiology, trans-arterial chemoembolization, trans-arterial radioembolization.

Full Text:

PDF

References


REFERENCES:

C. Aubé, A. Bouvier, J. Lebigot, L. Vervueren, V. Cartier, F. Oberti, Radiological treatment of HCC: Interventional radiology at the heart of management, Diagnostic and Interventional Imaging, Volume 96, Issue 6, 2015, 625-636, ISSN 2211-5684, https://doi.org/10.1016/j.diii.2015.04.008.

Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract. 2016;2016:5942306. doi: 10.1155/2016/5942306. Epub 2016 Feb 3. PMID: 26955390; PMCID: PMC4756136.

Reig M, Forner A, Rimola J, Fàbrega JF, Burrel M, Criado A, Robin K, Galle, Mazzaferro V, Salem R, Sangro B, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, Volume 76, Issue 3, 2022, Pages 681-693,ISSN 0168-8278,. https://doi.org/10.1016/j.jhep.2021.11.018.

Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. Br J Radiol. 2022 Sep 1;95(1138):20220379. doi: 10.1259/bjr.20220379. Epub 2022 Aug 4. PMID: 35867889; PMCID: PMC9815732

Ashish A, Amar M, Interventional Radiology in Hepatocellular Carcinoma: Current Status and Looking Ahead. Indographics 2022;1:184–195. DOI https://doi.org/10.1055/s-0042-1759556.

N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, Vicaut E, Trinchet JC, Sellier N, Beaugrand M, Seror O. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009 Nov;50(5):1475-83. doi: 10.1002/hep.23181. PMID: 19731239.

Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Rib-atti D. Molecular targeting agents associated with transarterialchemoembolization or radiofrequency ablation in hepatocarci- noma treatment. World J Gastroenterol 2014;20(2):486—97.

Seror O. hepatic ablation: what needs to be known in 2014. Diagn Interv Imaging 2014;95(7—8):665—75.

Qian GJ, Wang N, Shen Q, Sheng YH, Zhao JQ, Kuang M, et al. Efficacy of microwave versus radiofrequency ablation for treat-ment of small hepatocellular carcinoma: experimental andclinical studies. Eur Radiol 2012;22(9):1983—90.

Vogl TJ, Farshid P, Naguib NN, Zangos S, Bodelle B, Paul J, et al. Ablation therapy of hepatocellular carcinoma: a comparativestudy between radiofrequency and microwave ablation. AbdomImaging 2015,http://dx.doi.org/10.1007/s00261-015-0355-6.

Yu, Su Jong MD, PhDa; Yoon, Jung-Hwan MD, PhD; Lee, Jeong Min MD, PhDb; Lee, et al. Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. A matched case–control comparative analysis. Medicine 95(35):p e4551, August 2016. | DOI: 10.1097/MD.0000000000004551

Emmanuel A Tsochatzis, Evangelia Fatourou, James O’Beirne, Tim Meyer, and Andrew K Burroughs. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol. 2014 Mar 28;20(12): 3069–3077. Published online 2014 Mar 28. doi: 10.3748/wjg.v20.i12.3069

Kluger, M.D.; Halazun, K.J.; Barroso, R.T.; Fox, A.N.; Olsen, S.K.; Madoff, D.C.; Siegel, A.B.; Weintraub, J.L.; Sussman, J.; Jr, R.S.B.; et al. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplant. 2014, 20, 536–543.

Raoul J.-L., Forner A., Bolondi L., Cheung T.T., Kloeckner R., de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat. Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002

Sacco R, Conte C, Tumino E, et al. Trans arterial radioembolization for hepatocellular carcinoma: a review. J Hepatocellular carcinoma. 2016; 3: 25-29.

12. Yang B, Li, CL, Guo, Wh. Et al. intra arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer 18, 101(2018).


Refbacks

  • There are currently no refbacks.


© Copyright PJR 2008-